Affordable Access

deepdyve-link
Publisher Website

SKF83959 Has Protective Effects in the Scopolamine Model of Dementia.

Authors
  • Sheng, Gaofeng1
  • Zhang, Jinlin2
  • Gao, Shengfeng1
  • Gu, Yuanyuan1
  • Jiang, Bo3, 4
  • Gao, Qiufang3, 4
  • 1 Department of Pharmacy, The Second Affiliated Hospital of Nantong University.
  • 2 Department of Pharmacy, Affiliated Cancer Hospital of Nantong University.
  • 3 Department of Pharmacology, School of Pharmacy, Nantong University.
  • 4 Department of Pharmacy, The Third Affiliated Hospital of Nantong University.
Type
Published Article
Journal
Biological and Pharmaceutical Bulletin
Publisher
Pharmaceutical Society of Japan
Publication Date
Jan 01, 2018
Volume
41
Issue
3
Pages
427–434
Identifiers
DOI: 10.1248/bpb.b17-00877
PMID: 29491219
Source
Medline
Keywords
License
Unknown

Abstract

Patients with Alzheimer's disease (AD) always have cognitive impairments. In this study we investigated whether 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) has improvements on cognitive dysfunction. The scopolamine model of dementia was used to investigate the anti-amnesic activities of SKF83959, and then, Western blotting and pharmacological inhibitor were used to assay the anti-amnesic mechanisms of SKF83959. It was found that SKF83959 administration significantly improved the scopolamine-induced memory impairments in the passive avoidance task, Y-maze test, and Morris water maze task. Moreover, SKF83959 treatment significantly antagonized the down-regulating effects of scopolamine on brain-derived neurotrophic factor (BDNF) signaling cascade in the hippocampus, but not cortex. Importantly, the usage of K252a, a selective inhibitor of tyrosine kinase B (TrkB), significantly attenuated the protective effects of SKF83959 in the scopolamine model. Collectively, this study shows that SKF83959 has beneficial effects in the scopolamine model of dementia by modulation of hippocampal BDNF signaling, implying a novel and potential therapeutic agent for treating dementia in AD.

Report this publication

Statistics

Seen <100 times